Survival rates of head and neck cancers in Ghana: a retrospective study at the Komfo Anokye Teaching Hospital

Abstract

Objective: Data was collected to evaluate the survival rates of head and neck (conjunctiva, oropharyngeal and nonoropharyngeal) squamous cell carcinomas in Ghana. Data description: We provided data on a retrospective review of 8 years (January 2004 to December 2009) survival rate of head and neck squamous cell carcinomas (HNSCCs) at the Komfo Anokye Teaching Hospital in Ghana. The data consist of patient demographic data and clinicopathological findings which includes tumour site, tumour stage and histological grades of the patients. Clinical outcome measurement was death through to January 2013 on record and confirmed from the hospitals birth and death registry department. More than 85% of death cases were confirmed by gender, age, and folder identification numbers from the birth and death registry.

HSF1 activates the FOXO3a–ΔNp63α–CDK4 axis to promote head and neck squamous cell carcinoma cell proliferation and tumour growth

“…Recently, HNSCC therapy includes antibody treatment such as cetuximab against EGFR, pembrolizumab against programmed cell death protein 1, and nivolumab against programmed cell death protein ligand-1 [8][9][10]. Despite recent advances in the diagnosis and treatment of HNSCC, there has unsatisfied improvement in survival rates of HNSCC patients over the last few decades [11]. Therefore, it is important to explore new therapeutic targets or strategies for the treatment of HNSCC.…”